BioMarin Pharmaceutical Current Ratio 2006-2021 | BMRN

Current and historical current ratio for BioMarin Pharmaceutical (BMRN) from 2006 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. BioMarin Pharmaceutical current ratio for the three months ending June 30, 2021 was 5.32.
BioMarin Pharmaceutical Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $2.36B $0.44B 5.32
2021-03-31 $2.29B $0.43B 5.32
2020-12-31 $2.34B $0.49B 4.76
2020-09-30 $2.74B $0.86B 3.21
2020-06-30 $2.65B $0.81B 3.26
2020-03-31 $2.12B $0.82B 2.58
2019-12-31 $1.94B $0.93B 2.08
2019-09-30 $1.86B $0.49B 3.77
2019-06-30 $1.81B $0.44B 4.11
2019-03-31 $1.92B $0.50B 3.83
2018-12-31 $2.06B $0.52B 3.93
2018-09-30 $2.41B $0.84B 2.87
2018-06-30 $2.28B $0.81B 2.83
2018-03-31 $2.24B $0.77B 2.90
2017-12-31 $2.21B $0.82B 2.70
2017-09-30 $2.05B $0.42B 4.91
2017-06-30 $1.46B $0.37B 3.90
2017-03-31 $1.35B $0.34B 3.98
2016-12-31 $1.42B $0.44B 3.24
2016-09-30 $1.67B $0.38B 4.42
2016-06-30 $1.11B $0.37B 3.03
2016-03-31 $0.99B $0.39B 2.56
2015-12-31 $1.09B $0.45B 2.45
2015-09-30 $1.18B $0.39B 3.01
2015-06-30 $1.21B $0.35B 3.49
2015-03-31 $1.52B $0.31B 4.98
2014-12-31 $1.40B $0.24B 5.93
2014-09-30 $1.08B $0.21B 5.22
2014-06-30 $1.22B $0.17B 7.32
2014-03-31 $1.25B $0.16B 7.99
2013-12-31 $1.14B $0.18B 6.21
2013-09-30 $0.71B $0.17B 4.26
2013-06-30 $0.72B $0.14B 5.07
2013-03-31 $0.72B $0.14B 5.02
2012-12-31 $0.74B $0.17B 4.36
2012-09-30 $0.72B $0.14B 5.33
2012-06-30 $0.68B $0.12B 5.68
2012-03-31 $0.51B $0.12B 4.29
2011-12-31 $0.47B $0.09B 4.99
2011-09-30 $0.49B $0.08B 5.85
2011-06-30 $0.51B $0.08B 6.27
2011-03-31 $0.50B $0.08B 6.63
2010-12-31 $0.50B $0.08B 6.01
2010-09-30 $0.55B $0.09B 6.02
2010-06-30 $0.52B $0.08B 6.22
2010-03-31 $0.50B $0.08B 6.36
2009-12-31 $0.47B $0.08B 5.99
2009-09-30 $0.52B $0.06B 8.12
2009-06-30 $0.51B $0.06B 8.45
2009-03-31 $0.71B $0.13B 5.65
2008-12-31 $0.74B $0.13B 5.67
2008-09-30 $0.70B $0.12B 5.77
2008-06-30 $0.70B $0.06B 11.07
2008-03-31 $0.68B $0.05B 12.83
2007-12-31 $0.64B $0.06B 10.47
2007-09-30 $0.64B $0.05B 13.07
2007-06-30 $0.64B $0.05B 14.39
2007-03-31 $0.32B $0.04B 8.26
2006-12-31 $0.33B $0.05B 7.26
2006-09-30 $0.34B $0.04B 7.85
2006-06-30 $0.35B $0.04B 9.07
2006-03-31 $0.38B $0.06B 6.66
2005-12-31 $0.07B $0.04B 1.71
2005-09-30 $0.08B $0.04B 1.86
2005-06-30 $0.04B $0.04B 0.90
2005-03-31 $0.05B $0.05B 1.06
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $13.520B $1.860B
BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin's lead product, BM101, for the treatment of mucopolysaccharidosis-I, or MPS-I. Patients were treated with BM101 as part of a pivotal clinical trial completed to determine the safety and efficacy of the drug in humans.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76